About 30 results found for searched term "COX" (0.039 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1830 | Firocoxib | COX |
| ML 1785713 | ||
| Firocoxib is a selective COX-2 inhibitor exhibiting high selectivity to inhibit COX-2. | ||
| M1965 | Celecoxib | COX |
| SC 58635 | ||
| Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). | ||
| M2824 | Lumiracoxib | COX |
| COX-189 | ||
| Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. | ||
| M2984 | Rofecoxib | COX |
| MK 966 | ||
| Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM. | ||
| M3112 | Valdecoxib | COX |
| SC 65872 | ||
| Valdecoxib is a potent and selective inhibitor of COX-2 with IC50 of 5 nM. | ||
| M5858 | Parecoxib | COX |
| SC-69124 | ||
| Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. | ||
| M5859 | Parecoxib Sodium | COX |
| SC 69124A | ||
| Parecoxib Sodium (SC 69124A) is a potent and highly selective and orally active COX-2 inhibitor. Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. | ||
| M8173 | Salinomycin | Wnt/beta-catenin |
| Procoxacin; Sal | ||
| Salinomycin is a carboxylic polyether ionophore with antibiotic and anti-cancer properties. | ||
| M10301 | Fucoxanthin (UV>30%) | Others |
| Fucoxanthin is a carotenoid that occurs naturally in certain algae with anti-obesity, anti-oxidant, anti-diabetic, anticancer and anti-inflammatory activities. | ||
| M16840 | Secoxyloganin methyl ester | Iridoids |
| Secoxyloganin methyl ester | ||
| M16861 | Secoxyloganin | Iridoids |
| Secoxyloganin | ||
| M20423 | Etoricoxib | COX |
| MK-663; MK-0663; L-791456 | ||
| Etoricoxib is a new COX-2 selective inhibitor with anti-inflammatory, antipyretic, analgesic, and potential antineoplastic properties. | ||
| M20527 | Deracoxib | COX |
| SC-046 | ||
| Deracoxib is a COX-2 inhibitor with >48-fold selectivity over COX-1. It also exhibits inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3). | ||
| M20698 | Mavacoxib | COX |
| Trocoxil | ||
| Mavacoxib is a selective, long-acting cyclooxygenase-2 (COX-2) inhibitor. | ||
| M20769 | Desmethyl Celecoxib | COX |
| Desmethyl Celecoxib (compound 3b), an analog of Celecoxib with the optimal yield of 75%, is a selective inhibitor of cyclooxygenase-2 (COX-2) with anti-inflammatory activities. | ||
| M21500 | Polmacoxib | COX |
| CG100649 | ||
| Polmacoxib (CG100649) is a first-in-class, orally active non-steroidal anti-inflammatory compound (NSAID) that acts as a dual inhibitor. It inhibited COX-2 (IC50 ~ 0.1 μg/ml) and carbonic anhydrase. | ||
| M25413 | Fucoxanthin | Immunology/Inflammation |
| all-trans-Fucoxanthin | ||
| Fucoxanthin is a carotenoid that occurs naturally in certain algae with anti-obesity, anti-oxidant, anti-diabetic, anticancer and anti-inflammatory activities. | ||
| M29756 | Cimicoxib | COX |
| UR-8880 | ||
| Cimicoxib (CX) is an orally active potent and selective COX-2 (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar. | ||
| M41965 | COX-2-IN-30 | COX |
| COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). | ||
| M41966 | COX-1/2-IN-4 | COX |
| COX-1/2-IN-4 is anCOX inhibitorwith IC50 values of 0.239 μM and 0.191 μM for COX-1 enzyme and COX-2 enzyme , respectively. | ||
| M41969 | COX-2-IN-31 | COX |
| COX-2-IN-31 is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). | ||
| M41970 | COX-2-IN-33 | COX |
| COX-2-IN-33 is a COX-2 inhibitor (IC50=45.5 nM), as well as a potential anti-inflammatory agent. | ||
| M41971 | COX-1/2-IN-5 | COX |
| COX-1/2-IN-5 is a dual inhibitor of COX1/2 (IC50=2.650 μM, 0.958 μM), with anticancer activity. | ||
| M41972 | COX-2-IN-34 | COX |
| COX-2-IN-34 is a selective and orally active inhibitor of COX-2 , with an IC50 of 0.42 μM. | ||
| M42005 | COX-2/15-LOX-IN-2 | Lipoxygenase |
| COX-2/15-LOX-IN-2 is a potent dual COX-2 and 15-LOX inhibitor with IC50 values of 0.065?μM and 1.86?μM, respectively. | ||
| M42484 | COX-2/15-LOX-IN-3 | Lipoxygenase |
| COX-2/15-LOX-IN-3 is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. | ||
| M42485 | COX-2/15-LOX-IN-4 | Lipoxygenase |
| COX-2/15-LOX-IN-4 is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. | ||
| M45088 | Recombinant Human COX-2 Protein (Baculovirus-Insect, C-His) | Cytokines and Growth Factors |
| Cyclooxygenase-2 | ||
| COX-2 is s component of Prostaglandin-endoperoxide synthase (PTGS). It is the key enzyme in prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase. | ||
| M56350 | COX-2-IN-6 | COX |
| COX-2-IN-6 is an orally active, gut-restricted and selective cyclooxygenase-2 (COX-2) inhibitor for colorectal Chemoprevention of cancer. | ||
| M59515 | AIF Human Pre-designed siRNA Set | siRNA |
| apoptosis inducing factor mitochondria associated 1 | ||
| Human AIF Pre-designed siRNA Set contains three designed siRNAs for AIF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Gene ID: 9131 | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
